Trajectory of radiographic change over a decade

the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis

Andrew Allard, Anna Antony, Gavin Shaddick, Deepak R Jadon, Charlotte Cavill, Graham Robinson, Eleanor Korendowych, Neil McHugh, William Tillett

Research output: Contribution to journalArticle

1 Citation (Scopus)
4 Downloads (Pure)

Abstract

Objectives: To describe the trajectory of radiographic progression among patients with PsA who transitioned from conventional synthetic DMARDs to anti-TNF-α inhibitors in routine care.

Methods: A retrospective sample of patients with PsA (ClASsification criteria for Psoriatic ARthritis) was taken from the Bath longitudinal cohort. All patients had radiographs of the hands and feet taken: 5 years before (T0), at the time of (T1) and 5 years after (T2) commencing anti-TNF treatment. Radiographs were scored blinded using the PsA-modified Sharp-van der Heijde score (mSvdHS) and for osteoproliferation (Psoriatic Arthritis Ratingen Score) by A.Allard, A.Antony and W.T. This sample size was calculated to ensure 90% power to determine the smallest detectable difference of the mSvdHS to a 5% significance level. Cumulative probability plots were used to determine the probability of radiographic progression pre- (T0-T1) and post- (T1-T2) anti-TNF treatment.

Results: Eighty-four radiographs from 28 patients were selected for inclusion. The median [interquartile range (IQR)] disease duration at baseline (T0) was 8.5 (0-19.5) years. The interval between T0-T1 and T1-T2 was 4.2 years (3.34-6.65) and 4.9 years (4.25-5.87), respectively. The median mSvdHS at baseline (T0) was 8.5 (IQR 1.75-27.5). The median (IQR) rate of change in mSvdHS per year reduced after commencing anti-TNF, from 2.1 (0.88-3.92) between T0-T1 to 1.0 (IQR 0.05-2.35) between T1-T2 (P = 0.012).

Conclusion: The trajectory of damage accumulation over a 10-year period in this observational clinical cohort is low overall. The rate of radiographic damage as measured by the mSvdHS slows following commencement of anti-TNF.

Original languageEnglish
Pages (from-to)269-273
Number of pages5
JournalRheumatology
Volume58
Issue number2
Early online date20 Sep 2018
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

Psoriatic Arthritis
Antirheumatic Agents
Tumor Necrosis Factor-alpha
Baths
Sample Size
Foot
Hand
Therapeutics

Keywords

  • Anti-tumour necrosis factor (anti-TNF)
  • Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD)
  • Psoriatic arthritis
  • Radiographic progression

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Trajectory of radiographic change over a decade : the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis. / Allard, Andrew; Antony, Anna; Shaddick, Gavin; Jadon, Deepak R; Cavill, Charlotte; Robinson, Graham; Korendowych, Eleanor; McHugh, Neil; Tillett, William.

In: Rheumatology, Vol. 58, No. 2, 01.02.2019, p. 269-273.

Research output: Contribution to journalArticle

@article{af2c47ded7de4e619fa0d43917fd660e,
title = "Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis",
abstract = "Objectives: To describe the trajectory of radiographic progression among patients with PsA who transitioned from conventional synthetic DMARDs to anti-TNF-α inhibitors in routine care.Methods: A retrospective sample of patients with PsA (ClASsification criteria for Psoriatic ARthritis) was taken from the Bath longitudinal cohort. All patients had radiographs of the hands and feet taken: 5 years before (T0), at the time of (T1) and 5 years after (T2) commencing anti-TNF treatment. Radiographs were scored blinded using the PsA-modified Sharp-van der Heijde score (mSvdHS) and for osteoproliferation (Psoriatic Arthritis Ratingen Score) by A.Allard, A.Antony and W.T. This sample size was calculated to ensure 90{\%} power to determine the smallest detectable difference of the mSvdHS to a 5{\%} significance level. Cumulative probability plots were used to determine the probability of radiographic progression pre- (T0-T1) and post- (T1-T2) anti-TNF treatment.Results: Eighty-four radiographs from 28 patients were selected for inclusion. The median [interquartile range (IQR)] disease duration at baseline (T0) was 8.5 (0-19.5) years. The interval between T0-T1 and T1-T2 was 4.2 years (3.34-6.65) and 4.9 years (4.25-5.87), respectively. The median mSvdHS at baseline (T0) was 8.5 (IQR 1.75-27.5). The median (IQR) rate of change in mSvdHS per year reduced after commencing anti-TNF, from 2.1 (0.88-3.92) between T0-T1 to 1.0 (IQR 0.05-2.35) between T1-T2 (P = 0.012).Conclusion: The trajectory of damage accumulation over a 10-year period in this observational clinical cohort is low overall. The rate of radiographic damage as measured by the mSvdHS slows following commencement of anti-TNF.",
keywords = "Anti-tumour necrosis factor (anti-TNF), Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD), Psoriatic arthritis, Radiographic progression",
author = "Andrew Allard and Anna Antony and Gavin Shaddick and Jadon, {Deepak R} and Charlotte Cavill and Graham Robinson and Eleanor Korendowych and Neil McHugh and William Tillett",
year = "2019",
month = "2",
day = "1",
doi = "10.1093/rheumatology/key297",
language = "English",
volume = "58",
pages = "269--273",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Trajectory of radiographic change over a decade

T2 - the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis

AU - Allard, Andrew

AU - Antony, Anna

AU - Shaddick, Gavin

AU - Jadon, Deepak R

AU - Cavill, Charlotte

AU - Robinson, Graham

AU - Korendowych, Eleanor

AU - McHugh, Neil

AU - Tillett, William

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objectives: To describe the trajectory of radiographic progression among patients with PsA who transitioned from conventional synthetic DMARDs to anti-TNF-α inhibitors in routine care.Methods: A retrospective sample of patients with PsA (ClASsification criteria for Psoriatic ARthritis) was taken from the Bath longitudinal cohort. All patients had radiographs of the hands and feet taken: 5 years before (T0), at the time of (T1) and 5 years after (T2) commencing anti-TNF treatment. Radiographs were scored blinded using the PsA-modified Sharp-van der Heijde score (mSvdHS) and for osteoproliferation (Psoriatic Arthritis Ratingen Score) by A.Allard, A.Antony and W.T. This sample size was calculated to ensure 90% power to determine the smallest detectable difference of the mSvdHS to a 5% significance level. Cumulative probability plots were used to determine the probability of radiographic progression pre- (T0-T1) and post- (T1-T2) anti-TNF treatment.Results: Eighty-four radiographs from 28 patients were selected for inclusion. The median [interquartile range (IQR)] disease duration at baseline (T0) was 8.5 (0-19.5) years. The interval between T0-T1 and T1-T2 was 4.2 years (3.34-6.65) and 4.9 years (4.25-5.87), respectively. The median mSvdHS at baseline (T0) was 8.5 (IQR 1.75-27.5). The median (IQR) rate of change in mSvdHS per year reduced after commencing anti-TNF, from 2.1 (0.88-3.92) between T0-T1 to 1.0 (IQR 0.05-2.35) between T1-T2 (P = 0.012).Conclusion: The trajectory of damage accumulation over a 10-year period in this observational clinical cohort is low overall. The rate of radiographic damage as measured by the mSvdHS slows following commencement of anti-TNF.

AB - Objectives: To describe the trajectory of radiographic progression among patients with PsA who transitioned from conventional synthetic DMARDs to anti-TNF-α inhibitors in routine care.Methods: A retrospective sample of patients with PsA (ClASsification criteria for Psoriatic ARthritis) was taken from the Bath longitudinal cohort. All patients had radiographs of the hands and feet taken: 5 years before (T0), at the time of (T1) and 5 years after (T2) commencing anti-TNF treatment. Radiographs were scored blinded using the PsA-modified Sharp-van der Heijde score (mSvdHS) and for osteoproliferation (Psoriatic Arthritis Ratingen Score) by A.Allard, A.Antony and W.T. This sample size was calculated to ensure 90% power to determine the smallest detectable difference of the mSvdHS to a 5% significance level. Cumulative probability plots were used to determine the probability of radiographic progression pre- (T0-T1) and post- (T1-T2) anti-TNF treatment.Results: Eighty-four radiographs from 28 patients were selected for inclusion. The median [interquartile range (IQR)] disease duration at baseline (T0) was 8.5 (0-19.5) years. The interval between T0-T1 and T1-T2 was 4.2 years (3.34-6.65) and 4.9 years (4.25-5.87), respectively. The median mSvdHS at baseline (T0) was 8.5 (IQR 1.75-27.5). The median (IQR) rate of change in mSvdHS per year reduced after commencing anti-TNF, from 2.1 (0.88-3.92) between T0-T1 to 1.0 (IQR 0.05-2.35) between T1-T2 (P = 0.012).Conclusion: The trajectory of damage accumulation over a 10-year period in this observational clinical cohort is low overall. The rate of radiographic damage as measured by the mSvdHS slows following commencement of anti-TNF.

KW - Anti-tumour necrosis factor (anti-TNF)

KW - Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD)

KW - Psoriatic arthritis

KW - Radiographic progression

UR - http://www.scopus.com/inward/record.url?scp=85060621794&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/key297

DO - 10.1093/rheumatology/key297

M3 - Article

VL - 58

SP - 269

EP - 273

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 2

ER -